ホーム › 多発性骨髄腫 › ペンシルベニア › Philadelphia
Philadelphia、PAにおける多発性骨髄腫の臨床試験
Philadelphiaとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
被験者募集中第1相
- University of Pennsylvania Division of Hematology Oncology Perelman Center for Advanced Medicine, Philadelphia
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第3相
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
被験者募集中第4相
- University of Pennsylvania, Philadelphia
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第1/2相
- Penn Medicine, Philadelphia
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
被験者募集中第2相
- Fox Chase Cancer Center, Philadelphia
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
被験者募集中第1/2相
- Research Site, Philadelphia
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- Thomas Jefferson University Hospital, Philadelphia
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
被験者募集中第1相
- University of Pennsylvania, Philadelphia
Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment
被験者募集中第1/2相
- ECOG-ACRIN Cancer Research Group, Philadelphia
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
被験者募集中第1/2相
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
被験者募集中
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- Abramson Cancer Center University of Pennsylvania Medical Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
被験者募集中第1/2相
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
被験者募集中第2相
- Thomas Jefferson University Hospital, Philadelphia
Limited-duration Teclistamab
被験者募集中第2相
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
- Thomas Jefferson University, Honickman Center, Philadelphia
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
Philadelphiaにおける他の研究
- がん（全種類）59件の研究
- 乳がん56件の研究
- 非小細胞肺癌51件の研究
- 転移性癌46件の研究
- 大腸癌44件の研究
- 卵巣がん44件の研究
- 前立腺がん44件の研究
- 肺がん36件の研究
- 急性骨髄性白血病34件の研究
- 心不全31件の研究
- 子宮内膜がん28件の研究
- うつ病26件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。